Bacillus subtilis spores as adjuvants for DNA vaccines  by Aps, Luana R.M.M. et al.
BL
A
V
a
A
R
R
A
A
K
B
S
A
D
H
1
m
a
a
m
o
s
v
i
i
a
m
[
v
m
g
b
c
[
h
0Vaccine 33 (2015) 2328–2334
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
acillus  subtilis  spores  as  adjuvants  for  DNA  vaccines
uana  R.M.M.  Aps,  Mariana  O.  Diniz,  Bruna  F.M.M.  Porchia,  Natiely  S. Sales,
na  Carolina  R.  Moreno,  Luís  C.S.  Ferreira ∗
accine Development Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 12 April 2014
eceived in revised form 5 March 2015
ccepted 16 March 2015
vailable online 27 March 2015
eywords:
a  b  s  t  r  a  c  t
Recently,  Bacillus  subtilis  spores  were  shown  to be endowed  with  strong  adjuvant  capacity  when  co-
administered  with puriﬁed  antigenic  proteins.  In the  present  study  we  assessed  whether  spores  possess
adjuvant  properties  when  combined  with  DNA  vaccines.  We  showed  that  B. subtilis  spores  promoted
the  activation  of  dendritic  cells  in  vitro  and  induced  migration  of  pro-inﬂammatory  cells after  parenteral
administration  to mice.  Likewise,  co-administration  of  spores  with  a  DNA  vaccine  encoding  the  human
papillomavirus  type  16 (HPV-16)  E7 protein  enhanced  the activation  of antigen-speciﬁc  CD8+ T cellacillus subtilis
pores
djuvants
NA vaccine
PV-16
responses  in  vivo.  Mice  immunized  with  the DNA  vaccine  admixed  with  spores  presented  a  protec-
tive  immunity  increase  to  previously  implanted  tumor  cells,  capable  of expressing  HPV-16  oncoproteins.
Finally,  we  observed  that the  adjuvant  effect  can  vary  accordingly  to the  number  of  co-administered
spores  which  may  be  ascribed  with  the  ability  to induce.  Collectively,  the present  results  demonstrate
for  the  ﬁrst  time  that  B. subtilis  spores  can  also  confer  adjuvant  effects  to  DNA vaccines.
© 2015  Elsevier  Ltd.  All  rights  reserved.. Introduction
Adjuvants are essential elements in the composition of
ost vaccine formulations, particularly in subunit vaccines such
s those containing puriﬁed proteins or DNA vectors, which
re naturally endowed with low immunogenicity in mam-
alian species, especially in humans. Notably, the repertoire
f adjuvants for vaccines based on puriﬁed proteins has been
igniﬁcantly enlarged in the last years [1,2]. Concerning DNA
accines, several approaches have been tested to improve the
mmune responses induced in large mammalian hosts, such as
n vivo electroporation [3,4], codon usage optimization of the
ntigen-encoding sequence [5] and co-administration of plas-
ids encoding cytokines [6] or agonists of innate immunity
7–9]. The association of DNA vaccines with particulate adju-
ants, such as poly(lactic-co-glycolic) acid (PLGA) biodegradable
icroparticles, has been also shown to enhance the immuno-
enicity elicited by protein-based and DNA vaccines, which may
e related to their efﬁcient phagocytosis by antigen presenting
ells (APCs) including dendritic cells (DCs) and macrophages
10,11].
∗ Corresponding author. Tel.: +55 11 30917356.
E-mail address: lcsf@usp.br (L.C.S. Ferreira).
ttp://dx.doi.org/10.1016/j.vaccine.2015.03.043
264-410X/© 2015 Elsevier Ltd. All rights reserved.Bacillus subtilis spores have been successfully used as a probio-
tic for both humans and animals [12]. Moreover, B. subtilis spores
have been successfully employed as vectors for the mucosal deliv-
ery of vaccine antigens [13–16]. Recently, B. subtilis have been
shown to induce strong adjuvant effects after co-administration
with protein antigens either admixed or adsorbed at the spore
coat surface [17,18]. Nonetheless, no information is available
concerning the adjuvant effects of bacterial spores as adju-
vants for DNA vaccines, particularly for the induction of cellular
immune responses, an immunological hallmark of such vaccine
strategy.
In the present study, we  demonstrate that B. subtilis spores
display dose-dependent adjuvant effects on immune responses
induced in mice after parenteral administration with a DNA vac-
cine. As a model vaccine, we employed a DNA plasmid encoding
the human papillomavirus type 16 (HPV-16) E7 oncoprotein genet-
ically fused to the herpes simplex virus type 1 glycoprotein D (gD),
previously shown to confer preventive and therapeutic anti-tumor
immunity in mice [19–21]. Here we showed that B. subtilis spores
are capable to promote activation of DCs and induce a migratory
behavior of pro-inﬂammatory cell populations in mice. Further-
more, co-administration of spores increased both the activation of
antigen-speciﬁc CD8+ T cells and antigen-speciﬁc antibody produc-
tion. Altogether, the present evidences demonstrate that B. subtilis
spores display adjuvant effects when co-administered with DNA
vaccines.
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. Materials and methods
.1. Mice
Male C57BL/6 mice at 6–8 weeks of age were supplied by the
nimal Breeding Center of the Biomedical Sciences Institute of the
niversity of São Paulo and housed at the Parasitology Department
f the University of São Paulo. All of the procedures involving ani-
al  handling followed the recommendations for the proper use and
are of laboratory animals from the University of São Paulo Ethics
ommittee (protocol number 95-2011).
.2. TC-1 cell line
The TC-1 cell line was kindly provided by Dr. T.C. Wu  (John
opkins University, Baltimore, MD,  USA). This cell line is trans-
ected with retrovirus vectors encoding v-Ha-ras, HPV-16 E6 and
7 [22]. The TC-1 cells were propagated in DMEM medium sup-
lemented with 2 mM l-glutamine, 1 mM sodium pyruvate, 2 mM
on-essential amino acids, 10 mM HEPES buffer, 50 units/ml peni-
illin/streptomycin, 10% fetal bovine serum (FBS) and were kept at
7 ◦C at 5% CO2. Prior to inoculation, the TC-1 cells were harvested
y trypsinization, washed twice, and suspended in serum-free
edia at the proper cell concentration.
.3. DNA vaccine
The DNA vaccine pgDE7h encodes the HPV-16 E7 oncoprotein
enetically fused near the C terminal portion of the HSV-1 gD pro-
ein as previously described [20]. The gene sequence was  cloned
n the pUMVC3 vector (Aldevron, ND, USA), which contains a CMV
romoter and a kanamycin resistance-encoding gene.
.4. Preparation of spores
The sporulation of B. subtilis strain 1012 was  performed by the
utrient exhaustion method [23,24]. After 7 days of sporulation, the
ultures were centrifuged at 10,000 rpm for 10 min  and washed
hree times with distilled water. The spores were suspended in
ater and incubated for 1 h at 68 ◦C. The spores were visualized
nder a digital microscope EVOS® (AMG) and titrated to deter-
ine the number of colony-forming units (CFU/ml). The heat-killed
pores were obtained from autoclaving viable spores at 121 ◦C for
5 min.
.5. In vivo migration of pro-inﬂammatory cells
Mice were inoculated intraperitoneally with 5 × 108 live or
illed spores in 100 l of PBS. After 24 h, the peritoneal cavity
as washed with 10 ml  of PBS containing 2 mM EDTA and the
ollected cells were then incubated for 30 min  at 4 ◦C with PE-
abeled anti-Gr1, FITC-labeled anti-CD11b, APC-labeled anti-F4/80
nd PerCP-Cy5.5-labeled anti-Ly6C (BD Biosciences). The cells were
xamined by ﬂow cytometry using a FACS Canto (BD Biosciences)
nd data were analyzed using the FlowJo software (TreeStar, OR,
SA).
.6. Stimulation and activation of mouse DCs in vitro
Spleens and lymph nodes from naïve C57BL/6 mice were col-
ected and placed into a culture dish containing cold RMPI medium
upplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml
treptomycin. The spleens were carefully macerated. Large partic-
late matter was removed by passing the cell suspension through a
ell strainer 70 m nylon membrane. Cells were washed with ice-
old MACS buffers (PBS, 0.5% bovine serum albumin, 2 mM EDTA)33 (2015) 2328–2334 2329
and suspended in MACS buffer. Then, cells were incubated with
MicroBeads (Miltenyi Biotec) conjugated to hamster anti-mouse
CD11c monoclonal antibodies according to the manufacture’s pro-
tocols. Positively selected DCs contained >90% CD11c+ cells. For
stimulation, DC cells were incubated for 24 h in the presence of LPS
(100 ng/ml), DNA (1 g of pgDE7h) or three different concentra-
tions of live spores (2 × 106, 2 × 107 and 2 × 108). After this period,
the cells were stained with anti-CD11c, anti-I-A[b] (anti-MHCII),
anti-CD40, anti-CD80 and anti-CD86 conjugated to different ﬂu-
orochromes (BD Biosciences). The cells were examined by ﬂow
cytometry using FACS Fortessa (BD Biosciences) and data were ana-
lyzed using the FlowJo software (TreeStar, OR, USA). CD40, CD80
and CD86 expression values are shown from gated CD11c+MHCII+
cells. Data are shown as median ﬂuorescence intensity.
2.7. Cytometric bead array (CBA)
The cytokines levels in the supernatant of dendritic cells cultures
were measured after 24 h of stimulation. The test was conducted
with the CBA kit Th1/Th2/Th17 (BD Biosciences) according to the
manufacturer’s instructions for the quantiﬁcation of IL-2, IL-4, IL-
6, INF-, TNF-, IL-17A and IL-10. In summary, the sample and
the cytokine kit standards were mixed with microspheres coated
with capture antibodies speciﬁc for the respective cytokines. Then,
samples are incubated with the detection antibody labeled with
phycoerythrin (PE) for 2 h at room temperature and protected
from light. The ﬂow cytometric analysis was  based on the ﬂuo-
rescence intensity using FACS Fortessa (BD Biosciences). The data
were analyzed with the aid of the FCAP Array 3.0 to determine the
concentration (pg/ml) and means of ﬂuorescence intensities (MFI)
of the samples and standards.
2.8. Enzyme-linked immunosorbent assay (ELISA)
The anti-gD, anti-E7 and anti-spores antibody titers were mea-
sured by ELISA as previously described [25]. Plates were coated with
250 ng/well of puriﬁed truncated E7 fragment (amino acid 1 to 60)
or puriﬁed gD in MaxiSorp plates (Nunc). After incubation for 16 h
at 4 ◦C, the plates were blocked with 3% gelatin in PBS and incubated
at 37 ◦C for 2 h. Individual serum samples were added at the initial
1:10 dilution and subsequent two fold serial dilutions. Plates were
kept at 37 ◦C for 1 h. After incubation, anti-mouse IgG conjugated
to peroxidase (1:3000) was  added and the reaction was later devel-
oped with a solution containing O-fenilenodiaminadihidrocloreto
(OPD). The optical densities were determined at 492 nm in EpochTM
Multi-Volume Spectrophotometer (Bio Tek Instruments). All sam-
ples were assayed in duplicates and the absorbance values of
control reactions (wells without serum addition) were subtracted
from results obtained with the tested serum samples. Dilution
curves were drawn for each sample and the titers calculated as
the reciprocal values of the highest dilution with an optical density
of 0.1.
2.9. Immunization and tumor cell challenge
Groups of 5 mice were challenged subcutaneously (s.c.) with
7.5 × 104 TC-1 tumor cells suspended in 100 l of serum-free media
and injected into the right rear ﬂank of the animals. The mice
were vaccinated with one 40 g dose of the DNA vaccine (co-
administered with spores or not) 3 days after the implantation of
the tumor cells. The vaccine dose was applied into the tibialis ante-
rior muscle of each mice hind limb (divided in two 50 l aliquots).
Tumor growth was  monitored by visual inspection and palpation
three times a week for a period of 60 days. The animals were scored
as tumor-bearing when the tumors reached a size of approximately
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 mm in diameter. The mice were euthanized once the tumors
xceeded a diameter of 15 mm or became necrotic.
.10. Intracellular cytokine staining
Intracellular IFN- staining was performed from blood samples
ollected 7, 14, 21 or 28 days after the vaccine administration,
ccording to previously described procedures [20]. The blood sam-
les were treated for lysis of red blood cells and cultured at a
oncentration of 106 cells/well for 6 h at 37 ◦C in 96-well round
ottom microtiter plates with 10 g/ml of Brefeldin A (GolgiPlug;
D Biosciences, CA, USA) in the presence or not of 3 g/ml of the
7-speciﬁc RAHYNIVTF peptide (amino acids 49–57) [26]. After
ncubation, cells were stained with FITC-conjugated anti-CD8a
ntibody and after ﬁxation and permeabilization, with PE-labeled
nti-IFN-. The buffers and antibodies were purchased from BD
iosciences (CA, USA). The cells were examined by ﬂow cytome-
ry using a FACS Fortessa (BD Biosciences) and data were analyzed
sing FlowJo software (TreeStar, OR, USA).
.11. Statistical analyses
The ANOVA test was applied followed by Bonferroni’s post-test,
hen individual data points were compared.
. Results
.1. B. subtilis spores promote migration of pro-inﬂammatory
ells and DC activation in miceLive and heat-killed spores were tested for the migration of
ro-inﬂammatory cells after i.p. administration and subsequent
dentiﬁcation of different migratory cell populations. As indicated
ig. 1. B. subtilis spores induce pro-inﬂammatory cell migration in vivo. Cell recruitment 
illed spores (KS). Intraperitoneal CD11b+ and CD11b+Gr-1+ (A and C), F4/80+ and F4/80
noculation. (A and B) Number of stained cells recovered for different population as ind
xperiments with similar results. (C and D) Data are represented as dot plots from one re
f  stained cells from the total recovered cells. Statistical signiﬁcance: (*) p < 0.05, (**) p < 033 (2015) 2328–2334
in Fig. 1, both live (LS) and heat-killed spores (KS) induced a signif-
icant inﬂux of CD11b+ and CD11b+Gr1+ cells (Fig. 1A and C), which
may  represent neutrophils, eosinophils or immature myeloid cells,
also F4/80+ and F4/80+Ly6Chi cells (Fig. 1B and D), corresponding
to macrophages and inﬂammatory monocytes. No signiﬁcant inﬂux
of CD19+ or CD11c+ cells were detected in the peritoneal cavity of
mice inoculated with B. subtilis spores (data not shown).
In addition, we determined the capacity of spores to activate
mouse DCs after in vitro stimulation with different quantities of
spores. As presented in Fig. 2, CD11c+ MHCII+ DCs of naïve mice
exposed to the intermediate spores amount (2 × 107 LS) upregu-
lated the expression of the co-stimulatory receptors CD40 (Fig. 2A
and B) and CD80 (Fig. 2C and D) with regard to PBS treated
cells. No effects were observed with plasmid DNA  or at a higher
(2 × 108) spore dose, with no detectable ﬂuorescence enhancement
for the three tested markers. Also, DCs exposed to a lower (2 × 106)
spore dose enhanced the expression of CD40 but at a reduced
intensity with regard to the intermediate spore dose (Fig. 2B).
Inﬂammatory cytokines (TNF-  and IL-6) in cell culture super-
natants were detected in elevated values in cells exposed to LPS
and the two  highest spore concentrations. In contrast, only the
sample incubated with 2 × 108 LS showed measurable IL-10 val-
ues (Fig. 2D). Altogether, these results demonstrated that B. subtilis
spores can induce migration of murine pro-inﬂammatory cells and
DC activation, which further support the adjuvant effects of spores
co-administered with DNA vaccines.
3.2. Activation of CD8+ T cell responses and therapeutic
anti-tumor protection in mice co-administered with spores and
pgDE7h
To demonstrate that B. subtilis spores could also exert adju-
vant effects to DNA vaccines, we inoculated mice i.m. with spores
in naïve C57BL/6 mice after i.p. inoculation of 5 × 108 live spores (LS) or 5 × 108
+Ly6Chi (B and D) inﬂammatory cells were quantiﬁed by ﬂow cytometry 24 h after
icated. Data based on three animals per group and generated in two independent
presentative mice per group. Numbers in the upper corners show the percentages
.01, (***) p < 0.001, versus the group treated with PBS by ANOVA.
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Fig. 2. B. subtilis spores induce in vitro DC activation after stimulation with an intermediate spore amount. DCs (2 × 105 cells) puriﬁed from naïve mice lymphoid organs were
incubated with LPS (100 ng/ml), DNA (1 g of pgDE7 h) or three different concentrations of live spores (2 × 106, 2 × 107 and 2 × 108 LS). Non-treated cells were added with
the  same volume of PBS. Supernatants were collected after 24 h for measurements of cytokines production. Surface expression of CD40, CD80 and CD86 (APC) was measured
by  ﬂow cytometry after gating in CD11c+MHCII+ cells. Data are shown as histograms from one representative sample (A, C and E) or as Median Fluorescence Intensity (MFI)
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2 × 107) admixed with a plasmid DNA (pgDE7h) at a dose capable
f inducing low CD8+ T cell responses to the HPV-16 E7 oncopro-
ein and partial therapeutic protection to tumors in mice engrafted
ith the cells (TC-1) expressing HPV-16 oncoproteins [20]. Co-
dministration of spores and pgDE7h three days after implantation
f TC-1 cells signiﬁcantly enhanced the IFN- production by E7-
peciﬁc CD8+ T cells compared to mice immunized only with the
NA vaccine or spores separately (Fig. 3A and B). Mice inocu-
ated with live spores admixed with the pgDE7h showed higher
ctivation of antigen-speciﬁc CD8+ T cells in comparison to mice
o-inoculated with heat-killed spores (approximately a two-fold
ncrease). However, co-administration of pgDE7h with both live
nd killed spores conferred 80% therapeutic anti-tumor immunity,
 signiﬁcantly higher protection values with regard to mice immu-
ized with the same amount of DNA vaccine (40% survival) (Fig. 3C).
ltogether, these results show that B. subtilis spores enhance the
gDE7h-induced CD8+ T cell activation and T cell-mediated anti-
umor protective immunity.
.3. Dose-dependent adjuvant effects of B. subtilis on the
mmune responses induced by pgDE7h
The DC activation results suggest that the immune modulation
ffects of spores are dose dependent. Thus, we tested the effects
xert by different number of spores co-delivered with pgDE7h
egarding both activation of antigen-speciﬁc CD8+ T cells and
ntigen-speciﬁc antibody responses, as well as the anti-tumor pro-
ection effects (Fig. 4). The induction of E7-speciﬁc CD8+ T cell
esponses elicited in mice immunized with pgDE7h reached max-
mal values two weeks after immunization and was  detected with × 107 live spores (Fig. 4A). Accordingly, 80% of the mice co-
noculated with 2 × 107 spores and pgDE7h remained tumor-free,
hereas mice co-administered with 10-fold less or 10-fold more
pores showed lower anti-tumor protection levels (Fig. 4B).nduction after stimulation with the same conditions cited above. Data represented
rformed in triplicates. Statistical signiﬁcance: (*) p < 0.05, (**) p < 0.01, (***) p < 0.001
Different results were observed after measurement of the anti-
gD and anti-E7 antibody responses. Maximal anti-gD and anti-E7
serum IgG levels were achieved in mice immunized with pgDE7h
admixed with 2 × 106 spores (Fig. 4C and D).  Low anti-spores IgG
titers were observed only in mice immunized with the higher num-
ber of spores (Fig. 4E). These results suggest that the spore adjuvant
effects are dose dependent and require a speciﬁc balance of spores
and DNA in order to efﬁciently activate the different arms (CD8+
T lymphocytes or antibody production) of the adaptive immune
system.
4. Discussion
The adjuvant effects of B. subtilis spores have been previ-
ously reported using protein-based vaccines and were based on
the induction of antigen-speciﬁc antibody responses. Nonethe-
less, no study has been previously performed to investigate the
impact of spore administration in the enhancement of immune
responses induced by DNA vaccines. In addition, little is known
about the potential adjuvant effects of bacterial spores on the
cellular immune responses induced by vaccines. In this sce-
nario, our work has investigated both the ability of B. subtilis
spores to increase the immune responses induced by a DNA
vaccine and demonstrated experimentally that co-administration
of spores enhance the induction of cytotoxic responses induced
by vaccines. Based on a DNA vaccine encoding the HPV-16 E7
oncoprotein, our results demonstrated that both live and heat-
killed spores increased the activation of antigen-speciﬁc CD8+
T cells, as well as the functionality of the induced immune
response, measured by the vaccine-induced therapeutic anti-
tumor effects. Moreover, we  showed that B. subtilis spores activate
DCs, recruit pro-inﬂammatory cells, which is in accordance with
the immunomodulatory effects of spores both for puriﬁed proteins
and DNA vaccines. Finally, our results indicated that, regarding to
2332 L.R.M.M. Aps et al. / Vaccine 33 (2015) 2328–2334
Fig. 3. Co-administration of B. subtilis spores and pgDE7h induce enhanced E7-speciﬁc CD8+ T cell responses and therapeutic anti-tumor immunity. C57BL/6 mice were
immunized with 40 g of pgDE7h alone or admixed with 2 × 107 live (DNA + LS) or heat-killed (DNA + KS) spores or 2 × 107 LS or KS alone 3 days after the implantation of
TC-1  cells. (A and B) Frequencies of IFN-+-producing CD8+ T cells of PBMC pools were assessed two weeks after the immunization and after in vitro stimulation with or
without the E7-MHC class I peptide (49RAHYNIVTF57). (A) Data are represented as dot plots from one representative experiment. Numbers at the upper right corner indicate
the  percentage of CD8+ IFN-+ cells from total CD8+ T cells. (B) Data are presented as the percentage of CD8+ IFN-+ cells from total CD8+ T cells. The percentages of stimulated
samples were subtracted from unstimulated sample percentages. (C) Percentage of tumor-free mice 60 days after administration of the TC-1 cells. Data are based on the
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NA vaccines, the adjuvant effects of spores, including activation
ntigen-speciﬁc cellular responses and antibody production, are
ose-dependent in the murine host, requiring different amounts of
pores to induced maximal enhancement of the induced responses.
In our work, B. subtilis spores induced the migration of CD11b+,
D11b+Gr1+, F4/80+ and F4/80+Ly6Chi cells, indicating the attrac-
ion of neutrophils, immature myeloid cells, macrophages and
nﬂammatory monocytes to the inoculated mice peritoneal cav-
ty. Moreover, B. subtilis spores upregulated expression of CD40
nd CD86 co-activation markers in DCs. These results reinforce the
pplication of spores as vaccine adjuvants, since this category of
olecules increase the adaptive immune responses usually by acti-
ation of cells involved with the innate immune system. This fact is
specially relevant for particulate adjuvants, which require uptake
y APCs for proper enhancement of adaptive immune responses.
or instance, ∼1 m microparticles have been shown to be taken up
y APCs, such as DCs, in vivo, leading to migration to the T-cell area
f the draining lymph nodes and subsequent maturation [27]. In
articular, an efﬁcient DC-mediated endocytosis of B. subtilis spores
as been associated with enhanced priming of T cell responses
17]. Thus, spores seem to act as delivery system to APCs and pro-
ote direct activation of these cells, particularly for DCs. In fact, DCriment (n = 10). Statistical signiﬁcance: (**) p < 0.01, (***) p < 0.001 versus PBS group
exposed to B. subtilis spores induced up-regulation of MHC  I, MHC
II and co-stimulatory molecules, such as CD40, CD25 and CD86,
in the absence of exogenous stimulus [28–30]. The mechanisms
related to the spore adjuvant effects have also been attributed
to the DCs TLR-mediated signaling, particularly the TLR2 receptor
[28,30].
The interactions between spores and DCs have been shown to
induce a balanced Th1 and Th2 immune response pattern when
spores are co-administered with puriﬁed proteins and viral parti-
cles [17,28,29]. Moreover, the adjuvant effects of B. subtilis spores
have been reported to occur in a dose-dependent manner [17,29].
Using diverse antigens as models, the intensity of T cell prolifer-
ation and IgA and IgG production, increased proportionally to the
concentration of spores co-administered with the antigen [17,29].
In our study, both expressions of co-stimulatory molecules, CD8+ T
cell activation and anti-tumor immunity were achieved with an
intermediate spore concentration (2 × 107). On the other hand,
maximal induction of antigen-speciﬁc antibody responses was
achieved at a lower spore concentration. Notably, a larger amount
of spores (2 × 108) promoted down-regulation or no enhancement
of CD80 or CD40 and CD86 in DCs and promoted secretion of IL-
10, an immunosuppressive cytokine. Also, administration of the
L.R.M.M. Aps et al. / Vaccine 33 (2015) 2328–2334 2333
Fig. 4. Dose dependent adjuvant effects of B. subtilis spores. C57BL/6 mice were immunized with 40 g of pgDE7h or mixed with 2 × 106, 2 × 107 or 2 × 108 live spores (LS)
3  days after inoculation with TC-1 cells. (A) Data represent the percentage of CD8+IFN-+ T cell/total CD8+ T cells in PBMC samples collected from individual mice 7, 14,
21  and 28 days after the immunization and incubated in vitro with or without the E7-MHC class I peptide (49RAHYNIVTF57). Data are based on ﬁve animals per group
(n  = 5). The percentages of stimulated samples were subtracted from unstimulated sample percentages. (B) Data represent the percentage of tumor-free mice 60 days after
transplantation of tumor cells. Data were based on ﬁve animals per group of two independent experiments (n = 10). (C–E) Induction of anti-gD (C), anti-E7 (D) and anti-spores
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[E)  serum IgG responses in mice immunized with pgDE7h admixed or not with diffe
fter  the single dose. Data are based on ﬁve animals per group (n = 5). Statistical sig
NA vaccine combined to 2 × 108 spores did not increase tumor-
peciﬁc cellular and antibody responses, neither enhanced the
accine induced anti-tumor immunity, which may  correlate with
he in vitro immunosuppressive effects on DCs. Our study suggests,
herefore, that B. subtilis spores enhance both humoral and cellu-
ar (cytotoxic) immune response induced by DNA vaccines but the
djuvant effects are ﬁnely tuned by the amount of co-administered
pores. In conclusion, our study describes a novel immunobiologi-
al use of B. subtilis spores as particulate adjuvants for DNA vaccines.
n particular, our results raise interesting perspectives regarding
he enhancement of antigen-speciﬁc cytotoxic responses induced
y DNA vaccines, thus, representing an alternative tool for anti-
ancer and anti-viral vaccines.
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